10

DAFTAR PUSTAKA
Bahner JD, Cao LY, Korman NJ. Biologics in the management of psoriasis. Clin Cosmet lnvestig Dermatol 2009;2:11 1-28. Baumert TF, Thimme R, von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007;13:82-90. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C. et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res2010;62:749-54. Carroll M, Forgione M. Use of tumor necrosis factor a inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010;29:1021-9. Chung 5-J, Kim JK, Park M-C, Park Y-B, Lee 5-K. Reactivation of hepatitis B viral infection in inactive HBsAg carriers followinganti-tumor necrosis factor-a therapy. J Rheumatol 2009;36:2416-20. Fotiadou C, Lazaridou E, loannides D. Safety of anti-tumor necrosis factor-a agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011; 25:471-4. Gudjonsson JE, Elder JT. 2008. Psoriasis. In: Fitzpatrickset al editors. Dermatology in general medicine vol.1 7th ed. New York: McGraw-sHill Medical pp. 169-93. Harahap M. 2000. Ilmupenyakitkulit. Jakarta: Hipokrates pp. 116-26. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50. Prignano F, Ricceri F, Pescitelli L, Zanieri F, Lotti T. Tumor necrosis factor-alpha antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011;164:645-7. Ramos-Casals M. Therapy: Are TNF blockers safe for patients with hepatitis B virus infection? Nat Rev Rheumatol 2010;6:618-20.

11

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, lnadomi JM, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009;49:S4-12. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol2011;165:1037-43 Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airo P. Useof tumor necrosis factoralpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009;36:1 188-94.